Correlation Engine 2.0
Clear Search sequence regions

  • liver (1)
  • liver failure (1)
  • minor (1)
  • vemurafenib (4)
  • Sizes of these terms reflect their relevance to your search.

    The mitogen-activated protein kinase kinase 4 (MKK4) has recently been identified as druggable target for the treatment of acute liver failure in RNAi experiments. In these experiments MKK4 was identified to be a major regulator in hepatocyte regeneration. Inhibitors thereof may serve as medication to promote liver regeneration or reducing hepatocyte death. Just a small number of potent inhibitors with acceptable selectivity towards relevant off-targets are known up to date. Among the known potent inhibitors, selectivity is highly sensitive towards minor modifications of the molecule, which makes it necessary to carefully balance between potency and selectivity. In the herein presented study, a new class of Vemurafenib-derived inhibitors was investigated with α-carbolines as new scaffold. This new scaffold showed a remarkable intrinsic selectivity towards the chosen off-targets, without affecting potency towards MKK4 on a broad range of structural modifications. Copyright © 2022. Published by Elsevier Masson SAS.


    Michael Juchum, Bent Pfaffenrot, Philip Klövekorn, Roland Selig, Wolfgang Albrecht, Lars Zender, Stefan A Laufer. Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors. European journal of medicinal chemistry. 2022 Oct 05;240:114584

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35868124

    View Full Text